# A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

> **NCT00144495** · PHASE3 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 104 (actual)

## Conditions studied

- Chemotherapy Induced Anemia

## Interventions

- **DRUG:** recombinant human erythropoietin
- **DRUG:** recombinant human erythropoietin

## Key facts

- **NCT ID:** NCT00144495
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-11
- **Final completion:** 2005-05
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2009-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144495, "A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00144495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*